Background: Non-functioning pituitary adenoma (NFPA) is a challenging tumor. It is usually reached to a large size before it is clinically manifested. Operative interference is the first option in treatment of large N...Background: Non-functioning pituitary adenoma (NFPA) is a challenging tumor. It is usually reached to a large size before it is clinically manifested. Operative interference is the first option in treatment of large NFPA causing compressive manifestations but with frequent postoperative residual masses that is usually required additional treatment. Postoperative radiotherapy carried frequent side effects which open the door for postoperative medical treatment with dopamine agonist (DA) drugs based on the fact that these tumors have a variable amount of dopamine receptors. Lack of randomized, placebo-controlled trials prevents any conclusion on the efficacy of this drug. Its role in controlling postoperative proliferation and decreasing the rate of recurrence of NFPA is still questionable. Objective: Efficacy of bromocriptine (dopamine agonist (DA) drug) in reducing or preventing the re-growth of non-functioning pituitary adenoma NFPA after surgery. Methods: In this study, we examined the outcome of treating NFPA after surgery, with bromocriptine (dopamine agonists drug). This study was a retrospective review of consecutive patients that were treated by the authors at Assiut University Hospital between 2012-2018. All patients had postoperative Bromocriptine in a dose of 2.5 mg twice daily. Results: Thirty two patients were included in this study after they had surgery for NFPA. All patients had a residual mass documented by the immediate post operative MRI. After 6 months of postoperative bromocriptine treatment, and with comparing to immediate post operative images, eleven patients (34%) had mass reduction, thirteen patients (41%) of their residual masses remained unchanged and eight patients (25%) of the mass showed slight increase in size but not required re-surgery. After two years and throughout the follow up period, seven patients (22%) (all were males) had complete disappearance of the mass;ten patients (31%) had more reduction of the size of the mass (two of them were males) and four patients (13%) of the mass remained unchanged (none of them were males) and eleven patients (34%) had increase of the mass and they required re-surgery (two of them were males). Conclusion: Bromocriptine (DA drug) can play a role in reducing the size or preventing the re-growth of non-functioning pituitary adenoma after surgical debulking. Males showed noticeable response comparing to females. Its regular use might limit the need for surgery in this type of tumor. Further studies with large number of patients are highly recommended.展开更多
Introduction: Despite the fact that non-functioning pituitary adenomas do not overproduce hormones, many will stain positive for a particular pituitary hormone, which can be used to differentiate these adenomas into s...Introduction: Despite the fact that non-functioning pituitary adenomas do not overproduce hormones, many will stain positive for a particular pituitary hormone, which can be used to differentiate these adenomas into subgroups. If these different sub-groups behave differently in terms of post surgical progression of disease (PSPD) rates or other clinical variables, then better treatment and prognosis could be predicted. Methods: This was a retrospective cohort study. Patients who have undergone surgery for removal of a non-functioning pituitary adenoma at Emory University Hospital served as the source for all data used in this study (n = 184). Data were collected from a database of electronic medical records (EMRs) for these patients in 2010 documenting clinical and demographic variables including treatment and PSPD. Results: Risk for PSPD did not differ by adenoma subtypes: follicle-stimulating hormone (FSH+), luteinizing hormone (LH+), or those that do not stain positive for any hormone (non-functioning, or NF?) (p = 0.971). There were two clinical characteristics statistically related to adenoma subtype: altered mental status and the anterior-posterior (AP) dimension of pre-operative adenomas. PSPD was related to several clinical characteristics, including gender, previous adenoma, post-operative residual, and follow-up time.展开更多
目的横断面调查成人无功能性垂体腺瘤(non-functional pituitary adenoma,NFPA)术后垂体功能减退患者骨密度(bone mineral density,BMD)及身体成分的改变,进一步分析BMD与身体成分的关系。方法收集2018年11月至2020年1月就诊于中南大学...目的横断面调查成人无功能性垂体腺瘤(non-functional pituitary adenoma,NFPA)术后垂体功能减退患者骨密度(bone mineral density,BMD)及身体成分的改变,进一步分析BMD与身体成分的关系。方法收集2018年11月至2020年1月就诊于中南大学湘雅医院的成人NFPA术后垂体功能减退患者43例,并收集年龄、性别比、体质量指数(body mass index,BMI)匹配的健康对照组56例,测量所有研究对象BMI、腰围、腰臀比,采用双能X线骨密度仪(DEXA)评估腰椎及髋关节的BMD并分析骨骼肌质量及体脂含量。结果(1)垂体功能减退组腰椎L_(1~4)、股骨颈的BMD及Z值,全身总和骨矿含量均显著低于对照组(P<0.05)。(2)在男性,垂体功能减退患者的腰臀比、腰围身高比、躯干及全身脂肪百分比、脂肪指数显著高于对照组;在女性,垂体功能减退患者的腰围、腰臀比、躯干及全身脂肪百分比、A/G比率、躯干脂肪比/腿部脂肪比均显著高于对照组(P<0.05)。(3)Pearson相关性分析显示,四肢骨骼肌质量(ASM)、骨骼肌质量指数(SMI)与男性患者各部位的BMD呈显著正相关,躯干及全身脂肪百分比与女性患者髋部BMD呈显著负相关(P<0.05)。多元线性回归分析示,SMI是男性患者腰椎L_(1~4) BMD、股骨颈BMD、全髋关节BMD、全身骨矿含量的独立保护因素(P<0.05)。结论(1)成人无功能性垂体腺瘤术后发生垂体功能减退的患者出现骨密度减低及腹部脂肪沉积的风险增加。(2)骨骼肌质量及体脂对骨密度有重要影响,SMI是男性垂体功能减退患者腰椎与髋部骨密度、全身骨矿含量的独立保护因素。展开更多
文摘Background: Non-functioning pituitary adenoma (NFPA) is a challenging tumor. It is usually reached to a large size before it is clinically manifested. Operative interference is the first option in treatment of large NFPA causing compressive manifestations but with frequent postoperative residual masses that is usually required additional treatment. Postoperative radiotherapy carried frequent side effects which open the door for postoperative medical treatment with dopamine agonist (DA) drugs based on the fact that these tumors have a variable amount of dopamine receptors. Lack of randomized, placebo-controlled trials prevents any conclusion on the efficacy of this drug. Its role in controlling postoperative proliferation and decreasing the rate of recurrence of NFPA is still questionable. Objective: Efficacy of bromocriptine (dopamine agonist (DA) drug) in reducing or preventing the re-growth of non-functioning pituitary adenoma NFPA after surgery. Methods: In this study, we examined the outcome of treating NFPA after surgery, with bromocriptine (dopamine agonists drug). This study was a retrospective review of consecutive patients that were treated by the authors at Assiut University Hospital between 2012-2018. All patients had postoperative Bromocriptine in a dose of 2.5 mg twice daily. Results: Thirty two patients were included in this study after they had surgery for NFPA. All patients had a residual mass documented by the immediate post operative MRI. After 6 months of postoperative bromocriptine treatment, and with comparing to immediate post operative images, eleven patients (34%) had mass reduction, thirteen patients (41%) of their residual masses remained unchanged and eight patients (25%) of the mass showed slight increase in size but not required re-surgery. After two years and throughout the follow up period, seven patients (22%) (all were males) had complete disappearance of the mass;ten patients (31%) had more reduction of the size of the mass (two of them were males) and four patients (13%) of the mass remained unchanged (none of them were males) and eleven patients (34%) had increase of the mass and they required re-surgery (two of them were males). Conclusion: Bromocriptine (DA drug) can play a role in reducing the size or preventing the re-growth of non-functioning pituitary adenoma after surgical debulking. Males showed noticeable response comparing to females. Its regular use might limit the need for surgery in this type of tumor. Further studies with large number of patients are highly recommended.
文摘Introduction: Despite the fact that non-functioning pituitary adenomas do not overproduce hormones, many will stain positive for a particular pituitary hormone, which can be used to differentiate these adenomas into subgroups. If these different sub-groups behave differently in terms of post surgical progression of disease (PSPD) rates or other clinical variables, then better treatment and prognosis could be predicted. Methods: This was a retrospective cohort study. Patients who have undergone surgery for removal of a non-functioning pituitary adenoma at Emory University Hospital served as the source for all data used in this study (n = 184). Data were collected from a database of electronic medical records (EMRs) for these patients in 2010 documenting clinical and demographic variables including treatment and PSPD. Results: Risk for PSPD did not differ by adenoma subtypes: follicle-stimulating hormone (FSH+), luteinizing hormone (LH+), or those that do not stain positive for any hormone (non-functioning, or NF?) (p = 0.971). There were two clinical characteristics statistically related to adenoma subtype: altered mental status and the anterior-posterior (AP) dimension of pre-operative adenomas. PSPD was related to several clinical characteristics, including gender, previous adenoma, post-operative residual, and follow-up time.
文摘目的横断面调查成人无功能性垂体腺瘤(non-functional pituitary adenoma,NFPA)术后垂体功能减退患者骨密度(bone mineral density,BMD)及身体成分的改变,进一步分析BMD与身体成分的关系。方法收集2018年11月至2020年1月就诊于中南大学湘雅医院的成人NFPA术后垂体功能减退患者43例,并收集年龄、性别比、体质量指数(body mass index,BMI)匹配的健康对照组56例,测量所有研究对象BMI、腰围、腰臀比,采用双能X线骨密度仪(DEXA)评估腰椎及髋关节的BMD并分析骨骼肌质量及体脂含量。结果(1)垂体功能减退组腰椎L_(1~4)、股骨颈的BMD及Z值,全身总和骨矿含量均显著低于对照组(P<0.05)。(2)在男性,垂体功能减退患者的腰臀比、腰围身高比、躯干及全身脂肪百分比、脂肪指数显著高于对照组;在女性,垂体功能减退患者的腰围、腰臀比、躯干及全身脂肪百分比、A/G比率、躯干脂肪比/腿部脂肪比均显著高于对照组(P<0.05)。(3)Pearson相关性分析显示,四肢骨骼肌质量(ASM)、骨骼肌质量指数(SMI)与男性患者各部位的BMD呈显著正相关,躯干及全身脂肪百分比与女性患者髋部BMD呈显著负相关(P<0.05)。多元线性回归分析示,SMI是男性患者腰椎L_(1~4) BMD、股骨颈BMD、全髋关节BMD、全身骨矿含量的独立保护因素(P<0.05)。结论(1)成人无功能性垂体腺瘤术后发生垂体功能减退的患者出现骨密度减低及腹部脂肪沉积的风险增加。(2)骨骼肌质量及体脂对骨密度有重要影响,SMI是男性垂体功能减退患者腰椎与髋部骨密度、全身骨矿含量的独立保护因素。
